Reducing Non-Alcoholic Steatohepatitis

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-518334-88-00

Acronym

RedNASH2023

Enrollment

Registered

2024-10-08

Start date

Unknown

Completion date

Unknown

Last updated

2024-10-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic dysfunction-associated steatohepatitis

Brief summary

Decrease of a histological score of NASH

Detailed description

Decrease of fibrosis stage assessed by non-invasive liver elastography. Improvement of laboratory results and anthropometric data

Interventions

DRUGJardiance 10 mg film-coated tablets

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Decrease of a histological score of NASH	—

Secondary

Measure	Time frame
Decrease of fibrosis stage assessed by non-invasive liver elastography. Improvement of laboratory results and anthropometric data	—

Countries

Czechia

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026